Clinical trials: Neoplasms, Solid Tumor
Advanced Solid Tumors
A Study of AK157D1 for Injection in Advanced Solid Tumors
This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK157D1 for injection in advanced solid tumors.
- Trial name
- NCT07847281
- Testing
- AK157D1 for injection
- Where
- 3 sites in China
- Volunteers
- 243 people
- Sponsor
- Akeso
Obesity, Solid Neoplasm
Weight Management in Obese Cancer Patients During Curative Active Treatment
This is a feasibility study intervention to fifty cancer patients with obesity and with newly diagnosed stage II-IV solid tumors undergoing curative treatment recruited at the Catalan Institute of Oncology (ICO) in L'Hospitalet…
- Conditions
- Obesity, Solid Neoplasm, Stage II-IV, Curative Treatment
- Trial name
- CANOBESE (NCT07058207)
- Testing
- Multimodal weight management program
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Institut d'Investigació Biomèdica de Bellvitge
Cancer
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials
This study plans to include approximately 60-100 patients with advanced solid tumors who have progressed on clinical trial drugs. It will use an open-label, single-arm, multi-cohort umbrella design.
- Trial name
- NCT06612632
- Testing
- research drug in combination with Toripalimab, Toripalimab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Solid Tumor, BRAF V600 Mutation
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
This is a Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in patients with BRAF V600-Mutant advanced…
- Trial name
- NCT05501912
- Testing
- ABM-1310
- Where
- 10 sites in China
- Volunteers
- 20 people
- Sponsor
- ABM Therapeutics Shanghai Company Limited
Gastric Cancer, Gastroesophageal Junction Cancer
Study for AZD4360 in Participants With Advanced Solid Tumours
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06921928
- Testing
- AZD4360
- Where
- 14 sites in United States, China and 3 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
The purpose of this study is to test the safety of eribulin (Halaven™) and cyclophosphamide (Cytoxan®) given together at different doses.
- Conditions
- Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent, Neuropathy
- Trial name
- NCT01554371
- Testing
- Eribulin, Cyclophosphamide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
This is an open-label, phase I-II dose-escalation and expansion study designed to define the recommended dose of brigatinib as monotherapy in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors and to…
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor
- Trial name
- Briga-PED (NCT04925609)
- Testing
- Brigatinib
- Where
- 2 sites in France, Netherlands
- Volunteers
- 65 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphatic System Neoplasm
Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors
This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors.
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT07673614
- Testing
- Survey Administration, Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Michigan Rogel Cancer Center
Brain Metastases, Documented Her2 Overexpression
64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets
This is a single arm pilot study of 64Cu-MM-302 and unlabeled MM-302 in combination with trastuzumab in 10 patients with advanced HER2+ cancer with new or progressive brain metastases.
- Conditions
- Brain Metastases, Documented Her2 Overexpression, Advanced Solid Tumor, Neurologically Stable
- Trial name
- NCT02735798
- Testing
- MM-302, Trastuzumab
- Sponsor
- Pamela Munster
Neoplams
The Phase I Study of SIG001 Antibody on Cancer Therapy.
The goal of this clinical trial is to learn the safty characteristics of SIG001 Mab in cancer patients; It will also determine the Recommended Phase II dose of SIG001 Mab on cancer treatment, and pharmacological characteristics…
- Trial name
- NCT07486700
- Testing
- SIG001
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University
Solid Tumor, SGLT 2 Inhibitors
Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer
Revised version: Locally advanced or advanced solid tumors remain a major clinical challenge despite multimodal treatments, including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy.
- Trial name
- SGLT2SOLID (NCT07703163)
- Testing
- Canagliflozin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- West China Hospital
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic
This study investigates the well-being and health-related quality of life in cancer patients and survivors during the COVID-19 pandemic.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04500600
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 13,378 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Malignant Tumor
Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors
This study is a multi center, open label, dose increasing/dose expanding/efficacy expanding phase I clinical trial aimed at evaluating the safety, tolerance, PK characteristics, and anti-tumor efficacy characteristics of HRS-2189…
- Trial name
- NCT05851092
- Testing
- HRS-2189 Tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Advanced Solid Tumor
Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors
The purpose of this trial is to evaluate the safety and tolerability of Utidelone Capsule in patients with advanced solid tumors and determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).
- Trial name
- NCT05681000
- Testing
- Utidelone Capsule
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Biostar Pharma, Inc.
Ovarian Cancer
A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer
This is non randomised, open label, dose finding, efficacy and safety study, enrolling patients with advanced (stage III and IV) ovarian cancer It will be conducted in two successive phases. Phase II has a two-step design
- Trial name
- NCT00831636
- Testing
- CP-4055
- Where
- 5 sites in Belgium, Italy
- Volunteers
- 28 people
- Sponsor
- Clavis Pharma
Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm
Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit
This study investigates the use electroencephalography (EEG - a test that measures brain waves) to learn if patients who appear unresponsive (do not respond to noises, words, or touch) retain any consciousness.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT05091632
- Testing
- Electroencephalography, Questionnaire Administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma, Glioblastoma
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
- Conditions
- Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer
- Trial name
- NCT05131763
- Testing
- NKG2D-based CAR T-cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Fudan University
Leptomeningeal Metastases
Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease
This pilot clinical trial studies continuous intraventricular methotrexate in treating patients with leptomeningeal disease. Drugs used in chemotherapy, such as methotrexate, work in different ways to stop the growth of cancer…
- Trial name
- NCT01438021
- Testing
- pharmacological study, methotrexate
- Sponsor
- City of Hope Medical Center
Cancer
A Phase 1 Study of ARQ 197 in Patients With Solid Tumors
This is a Phase 1, open label, dose escalation study of ARQ 197 in patients with advanced/recurrent solid tumors. The purpose of this study is to determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.
- Trial name
- NCT00609921
- Testing
- ARQ197
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Tumors With Aberrations in ALK or ROS1
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
The purpose of this signal seeking study was to determine whether treatment with ceritinib demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
- Trial name
- SIGNATURE (NCT02186821)
- Testing
- Ceritinib
- Where
- 21 sites in United States
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.